Alaunos Therapeutics

ACTIVE

2617 Bissonnet St Ste 225, Houston, Texas, United Stateswww.alaunos.comPublic1–10 employees$4.5M

Also known as:

tcrt

tcrt-us

alaunos therapeutics, inc.

alaunos

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

Clinical Trials

0 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

73.0%

Phase 2

16.2%

Phase 3

5.4%

Trial Status Distribution

Completed

46.0%

Suspended

2.7%

Terminated

16.2%

Unknown

32.4%

Withdrawn

2.7%

Clinical Trials

Trials sponsored by this organization (37)

Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs

Completed

observational

Mar 20237 participants

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Phase 1

Terminated

interventional

Apr 20228 participants

HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors

Terminated

observational

Sep 202119 participants

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

Phase 2

Terminated

interventional

Aug 201940 participants

Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102

Phase 1

Completed

interventional

Sep 201836 participants

A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102

Phase 1

Completed

interventional

Jun 201821 participants

A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG

Phase 1

Terminated

interventional

Sep 20176 participants

A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer

Phase 1

Terminated

interventional

Jul 20159 participants

Page 1 of 5

Approvals

No approval data available

News

Alaunos Therapeutics Reports Promising Preclinical Data for Non-Hormonal Obesity Drug ALN1003

- Alaunos Therapeutics announced positive preclinical results for ALN1003, showing up to 12.9% body weight reduction in diet-induced obesity mouse models. - The oral small-molecule drug demonstrated significant liver weight reductions of up to 55% and improvements in liver injury biomarkers compared to controls. - ALN1003 offers a differentiated non-hormonal approach to obesity treatment, potentially providing an alternative to current hormone-based therapies like GLP-1 drugs. - The company plans to advance toward IND-enabling studies while optimizing formulations and manufacturing processes with current cash runway extending into Q2 2026.

Mar 2, 2026

Back to Organizations